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http://dxObjectives: The timing for mitral valve surgery in asymptomatic patients with severe mitral regurgitation and
preserved left ventricular function remains controversial. We analyzed the immediate and long-term outcomes
of these patients after surgery.
Methods: From January 1992 to December 2012, 382 consecutive patients with severe chronic degenerative
mitral regurgitation, with no or mild symptoms, and preserved left ventricular function (ejection fraction
60%) were submitted to surgery and followed for up to 22 years (3209 patient-years). Patients with associated
surgeries, other than tricuspid valve repair, were excluded. Cox proportional-hazard survival analysis was
performed to determine predictors of late mortality and mitral reoperation. Subgroup analysis involved patients
with atrial fibrillation or pulmonary hypertension.
Results: Mitral valvuloplasty was performed in 98.2% of cases. Thirty-day mortality was 0.8%. Overall
survival at 5, 10, and 20 years was 96.3%  1.0%, 89.7%  2.0%, and 72.4%  5.8%, respectively, and
similar to the expected age- and gender-adjusted general population. Patients with atrial fibrillation/pulmonary
hypertension had a 2-fold risk of late mortality compared with the remaining patients (hazard ratio, 2.54; 95%
confidence interval, 1.17-4.80; P ¼ .018). Benefit was age-dependent only in younger patients (<65 years;
P ¼ .016). Patients with atrial fibrillation/pulmonary hypertension (hazard ratio, 4.20, confidence interval,
1.10-11.20; P ¼ .037) and patients with chordal shortening were at increased risk for reoperation, whereas
patients with P2 prolapse (hazard ratio, 0.06; confidence interval, 0.008-0.51; P ¼ .037) and patients with
myxomatous valves (hazard ratio, 0.072; confidence interval, 0.008-0.624; P ¼ .017) were at decreased risk.
Conclusions: Mitral valve repair can be achieved in the majority of patients with low mortality (<1%)
and excellent long-term survival. Patients with atrial fibrillation/pulmonary hypertension had compromised
long-term survival, particularly younger patients (aged <65 years), and are at increased risk of mitral
reoperation. (J Thorac Cardiovasc Surg 2014;148:2795-801)A
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DMitral valve (MV) surgery is recommended for symptom-
atic patients with severe primary mitral regurgitation
(MR), and MV repair is the procedure of choice whenever
it is feasible and expected to be durable.1,2 The
management of patients with degenerative MR has
changed dramatically during the past 2 decades, mainly
because of the refinement and standardization of MV
repair techniques that led to predictable and durable
results. In centers of excellence, the reparability rate can
reach approximately 100% and operative mortality is less
than 1% in selected cases, such as isolated P2 prolapse,e Center of Cardiothoracic Surgery, University Hospital and Medical School,
bra, Portugal.
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The Journal of Thoracic and Carand the need for reoperation because of repair failure in
the long-term may be as low as 5%.3-5 Finally, the
extensive knowledge of the natural history of MR and
the dire consequences when it is left untreated propelled
the rationale to intervene early, before complications
supervene.
However, indications for mitral surgery, as expressed in
the current guidelines, were based on levels of evidence B
and C (consensus opinion of experts and retrospective
studies), and not on randomized clinical trials (level A).
This becomes even more critical in asymptomatic patients
without signs of left ventricular (LV) deterioration. Two
lines of thought have emerged on how to deal with this
particular group of patients, one more conservative, also
referred to as ‘‘watchful waiting,’’ mainly based on a report
from Rosenhek and colleagues,6 who advocated delay of
surgery until the end points expressed in the guidelines
are reached. By contrast, others have proposed a more
proactive attitudewith the argument that early surgery saves
the patient from the unnecessary risks associated with
chronic MR.7 They suggest that these patients should bediovascular Surgery c Volume 148, Number 6 2795
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CI ¼ confidence interval
HR ¼ hazard ratio
LV ¼ left ventricular
MR ¼ mitral regurgitation
MV ¼ mitral valve
NYHA ¼ New York Heart Association
PHT ¼ pulmonary hypertension
SPAP ¼ systolic pulmonary artery pressure
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Dreferred to highly skilled centers for MV repair. Few studies
have reported the long-term clinical behavior of asymptom-
atic patients with severe chronic MR and preserved LV
function who underwent MV surgery, currently considered
class IIb indications (surgery may be considered; useful-
ness/efficacy is less well established by evidence/opinion)
in the European Guidelines1 and class IIa (surgery should
be considered; weight of evidence/opinion is in favor of
usefulness/efficacy) in the American guidelines.2 There-
fore, we aimed at evaluating our perioperative and
long-term (up to 22 years) outcomes in this population
and identifying predictors of impaired survival that could
lead to changes on the timing for mitral surgery.METHODS
Patient Population and Data Collection
From January 1992 to December 2012, 2126 patients with severe
pure or predominant MR underwent MV surgery, 382 of whom were
asymptomatic or mildly symptomatic, in New York Heart Association
(NYHA) class I or II, and had severe degenerative MR (3þ) and
preserved LV function. These patients constitute the object of this study.
All patients underwent isolated mitral surgery, with or without concom-
itant tricuspid valve annuloplasty for functional regurgitation. Patients with
other associated procedures were excluded from this analysis. Also
excluded were patients in NYHA class III or IV, with LVejection fraction
less than 60% and LVend-systolic internal diameter 45 mm or greater, and
patients with coronary artery disease, aortic valve disease, hypertrophic
cardiomyopathy, ascending aortic aneurysms, and previous mitral surgery.
Data were retrieved from a dedicated database and included relevant
preoperative demographic, clinical, and echocardiographic variables;
surgical information; and postoperative records. A thorough investigation
of all operation reports was undertaken to separate accurately the various
forms of degenerative MV disease—myxomatous (including Barlow’s
disease), fibroelastic disease, and isolated annular dilatation—and the
valve segments involved.
Myxomatous involvement was seen as those valves with thickened and
opaque leaflets, moderate enlargement of the annulus, and sometimes
thickened and elongated/ruptured chordae. Barlow’s valves were defined
as those with severe myxoid infiltration, severe annular dilatation, multiple
segments of prolapse and billowing, and thin or thickened elongated
chordae. Fibroelastic disease was defined as those valves with thin leaflets,
fairly normal sizes, and translucence, with the exception of the prolapsed
segment, and the chordae were often thin and ruptured.
Follow-up information was collected through a mailed questionnaire
or by telephone interview with surviving patients, family members, or2796 The Journal of Thoracic and Cardiovascular Surthe patient’s personal physician, and included vital status and need for
MV reoperation. The cumulative follow-up for the entire cohort was
3732 patient-years (mean, 8.6  7.5 years; range, 0.6-21.9 years) and
was complete for 98% of the patients.
Echocardiographic Evaluation
All patients had a detailed echocardiographic examination preopera-
tively, and Doppler examinations and the severity of MR were analyzed.
In the earlier years, it was assessed qualitatively (valve morphology: flail
leaflet, large coaptation defect; reversal of pulmonary vein flow) and
semiquantitatively (size of the regurgitant jet in the left atrium, regurgitant
jet area). In recent years, other methods, such as the vena contracta,
regurgitant volume, and effective regurgitant orifice area, have been used
more frequently. Left chamber dimensions, LV function (fractional
shortening, ejection fraction), and systolic pulmonary artery pressure
(SPAP) were measured as recommended.8 Intraoperative transesophageal
echocardiography, both pre- and post-repair, was routinely used from the
beginning of the study, and no patient left the operating room with greater
than mild MR.Operative Findings and Procedure
The operation was standardized for all patients, including cardiopulmo-
nary bypass with moderate hypothermia (28C-30C) and intermittent
antegrade cold crystalloid cardioplegia through the aortic root. MV
exposure was through a left atriotomy, posterior to the Waterston’s groove
in the majority of cases. In a few cases, the valve was reached through the
right atrium and interatrial septum.
A comprehensive valve analysis of all the MV components was
performed routinely. Myxomatous pathology involved 272 patients
(71.2%), of whom 65 (17.0%) had severe myxomatous involvement
(Barlow’s disease). Isolated posterior prolapse was present in 211 patients
(55.2%), isolated anterior prolapsewas present in 50 patients (13.1%), and
bileaflet prolapse was present in 102 patients (26.7%). Segment P2 was
the most frequently involved (268 patients, 70.2%), followed by A2
(106 patients, 27.7%). Repair was oriented to correct all lesions causing
mitral dysfunction, following the classic Carpentier principles.Statistical Analysis
Continuous variables are reported as mean  standard deviation and
compared by a Student t test or Mann–Whitney U test. Categoric variables
are reported as percentages and were compared using chi-square tests.
Actuarial survival and survival free of mitral reoperation were plotted using
the Kaplan–Meier method, and group comparison, when available, was
made using log-rank analysis. Multivariate analysis to identify independent
risk factors for time-dependent events was performed using a stepwise
Cox proportional hazards multivariable model and included clinical,
echocardiographic, and operative variables. Criteria for entry and retention
in the multivariable models were set at the 0.1 and 0.05 confidence level,
respectively.
For each patient included in the study, the corresponding average age-
and gender-specific annual mortality of the Portuguese general population
was obtained (National Institute of Statistics, census 2012). On the basis of
these mortality data, the probability of cumulative expected survival was
ascertained and an expected survival curve was built. Comparison was
made using a 1-sample log rank test.
A subgroup analysis was undertaken for patients with atrial fibrillation
(AF) or pulmonary hypertension (PHT), defined as an SPAP at rest greater
than 50 mm Hg. Patients with AF/PHT were treated as a composite
covariate to be accommodated in class of IIa recommendation for mitral
surgery of the American Heart Association/American College of
Cardiology and European Society of Cardiology/European Association
for Cardio-Thoracic Surgery guidelines. These patients were compared
with the remaining patients, but because the groups were different in agegery c December 2014
TABLE 1. Selected preoperative patient characteristics for the overall
population
Characteristics N (%)
Age (mean  SD) 55.7  14.2
Male 279 (73.0)
NYHA class I 272 (71.2)
NYHA class II 110 (28.8)
Previous stroke 13 (3.4)
Hypertension 106 (27.7)
Diabetes mellitus 10 (2.6)
Chronic obstructive pulmonary disease 18 (4.7)
AF 64 (16.8)
Patients with AF or PHT 106 (24.4)
Patients without AF or PHT 276 (63.6)
Echocardiographic findings
Tricuspid regurgitation (>2þ) 42 (9.7)
Ejection fraction (%) 69.8  7.5
Left ventricle systolic diameter (mm) 37.2  4.2
Left ventricle diastolic diameter (mm) 62.0  6.6
Left atrium diameter (mm) 50.8  8.5
Systolic pulmonary arterial pressure (mm Hg) 43.0  14.2
AF, Atrial fibrillation; NYHA, New York Heart Association; PHT, pulmonary
hypertension; SD, standard deviation.
TABLE 2. Operative data of the overall population
Characteristics N (%)
MV cause/anatomy
Myxomatous 272 (71.2)
Barlow’s disease 65 (17.0)
Fibroelastic deficiency 96 (25.1)
Isolated annular dilatation 14 (3.7)
Isolated anterior prolapse 50 (13.1)
Isolated posterior prolapse 211 (55.2)
Bileaflet prolapse 102 (26.7)
Chordal rupture 210 (55.0)
Surgery
MV repair 375 (98.2)
MV replacement
Study population 7 (1.8)
Study period* 21 (3.4)
Ring annuloplasty 364 (95.3)
Leaflet resection 271 (70.9)
Artificial chordae
Anterior leaflet 109 (28.5)
Posterior leaflet 30 (7.9)
Chordal transfer/shortening 29 (7.4)
Commissural closure 33 (8.6)
Papillary muscle shortening 20 (5.2)
Tricuspid annuloplasty 30 (7.9)
MV, Mitral valve. *During the study period, 615 patients with severe MR (including
all causes), without previous MV surgery, in NYHA class I/II, and with preserved LV
function underwent isolated MV surgery (tricuspid repair was included).
Coutinho et al Acquired Cardiovascular Diseaseand other important demographic and clinical variables, we performed an
individual matching of patients (1:1) in both groups according to age
(3 years difference admitted), sex, and relevant comorbidities (renal failure,
hypertension, chronic obstructive pulmonary disease, and cerebrovascular
disease), obtaining 106 patients in each arm. AF and PHT (or SPAP value)
were not included separately in the multivariate analysis to avoid
multicollinearity with the described composite outcome. The data were
analyzed using SPSS version 20 (SPSS Inc, Chicago, Ill).A
C
DRESULTS
Baseline Characteristics
The clinical and echocardiographic characteristics of the
382 patients who met the inclusion criteria are shown in
Table 1. The mean age of patients was 55.5  14.2 years,
male gender predominated (74.7%), and 106 patients
(24.4%) had AF or PHT (subgroup analysis). These
patients were older (63.3  11.9 years vs 52.8  14 years,
P < .0001), were more often hypertensive (35.8% vs
25.0%, P¼ .034), and had a higher incidence of fibroelastic
deficiency (34.4% vs 23.2%, P<.0001) compared with the
remaining patients. After case-matching, we obtained 2
well-balanced groups for comparison, except in their
distinctive features (AF and PHT). However, patients with
AF/PHT had larger left atria (56.2 vs 48.7 mm, P<.0001).Details of Mitral Valve Surgery
Surgical data are presented in Table 2. MV repair was
achieved in 375 patients (98.2%). Leaflet resection was
performed in 271 patients (70.9%), and posterior leaflet
sliding plasty was performed in 31 patients (8.1%).
Artificial polytetrafluoroethylene (Gore-Tex; WL Gore &
Associates Inc, Flagstaff, Ariz) chordae (initially size 4-0,The Journal of Thoracic and Carmore recently size 5-0) were implanted in 139 patients
(36.4%). A prosthetic ring (Carpentier-Edwards Physio;
Edwards Lifesciences Corporation, Irvine, Calif) was
used in the majority of patients (95.9%), with a mean size
of 32.8 mm (range, 28-38 mm). Patients with myxomatous
disease had larger rings implanted (P<.001). A modified
De Vega9 tricuspid annuloplasty was performed in 30
patients (7.9%).
MV replacement was necessary in 7 patients, all with
intense calcium infiltration of the leaflets or mitral annulus.
Four of these patients had bileaflet prolapse, but only 1
patient with Barlow’s disease had the valve replaced. The
subvalvular apparatus was preserved in all but 1 patient
because of heavily calcified chordae and papillary muscles.Early Mortality and Long-Term Survival
Thirty-day mortality was 0.8% (3 patients); 1 patient
died of cerebrovascular accident, and 2 patients died of
cardiac causes. Overall survival at 5, 10, 15, and 20 years
was 96.3%  1.0%, 89.7%  2.0%, 83.3%  3.0%,
and 72.4%  5.8%, respectively. These survivals were
better than those of the expected age- and gender-adjusted
Portuguese standard population (Figure 1).
The Cox analysis identified age (hazard ratio [HR], 1.07;
95% confidence interval [CI], 1.03-1.11; P ¼ .001),
chronic pulmonary obstructive disease (HR, 3.43; 95%diovascular Surgery c Volume 148, Number 6 2797
FIGURE 1. Overall survival of the study population compared with the
gender- and age-matched Portuguese standard population. Pts, Patients.
TABLE 4. Predictors of mitral reoperation
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Myxomatous
valves
0.16 (0.03-0.76) .021 0.07 (0.01-0.62) .017
Diabetes 2.43 (1.84-4.44) .025 — —
AF/PHT 3.82 (1.02-10.32) <.0001 4.20 (1.10-11.20) .037
SPAP 1.04 (1.01-1.08) .046 Not included
AL prolapse 3.12 (1.80-10.67) .001 — —
PL prolapse 0.06 (0.01-0.26) <.001 — —
P2 prolapse 0.05 (0.01-0.34) .003 0.06 (0.01-0.51) .037
PL resection 0.23 (0.12-0.61) .001
Chordal
shortening
1.70 (1.23-3.12) .014 9.09 (1.16-18.12) .045
AF, Atrial fibrillation; AL, anterior leaflet; CI, confidence interval; HR, hazard ratio;
PHT, pulmonary hypertension; PL, posterior leaflet; SPAP, systolic pulmonary artery
pressure.
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DCI, 1.30-9.05; P ¼ .013), and AF/PHT (HR, 2.54; 95% CI,
1.17-4.80; P¼ .018) as independent factors of late mortality
(Table 3).Mitral Valve Reoperation
There were 2 early (in-hospital) failures of theMV repair,
and in both cases we were able to re-repair and preserve the
valve. Ten patients (2.6%) required MV reoperation for
significant MR late after the primary procedure. The
mean time from the first surgery to the reoperation was
8.6  5.1 years. The valve had to be replaced in 8 cases.
The main intraoperative findings were marked posterior
leaflet retraction conditioning, lack of central coaptation,
ring dehiscence, native and artificial chordae rupture,
endocarditis with severe leaflet and chordal destruction,
and leaflet calcification.TABLE 3. Predictors of late mortality (Cox proportional hazards
analysis)
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.09 (1.05-1.13) <.0001 1.07 (1.03-1.11) .001
Myxomatous
valves
0.50 (0.26-6.79) .035 — —
COPD 4.16 (1.61-10.76) .003 3.43 (1.30-9.05) .013
AF 3.58 (1.86-6.88) <.0001 Not included
AF/PHT 3.57 (1.88-6.79) <.0001 2.54 (1.17-4.80) .018
TR (2þ) 4.08 (1.73-9.60) .001 — —
LA dimension 1.07 (1.03-1.11) .001 — —
SPAP 1.03 (1.01-1.05) .003 Not included
P2 prolapse 0.47 (0.24-0.90) .024 — —
AF, Atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary
disease; HR, hazard ratio; LA, left atrium; PHT, pulmonary hypertension;
SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation.
2798 The Journal of Thoracic and Cardiovascular SurFreedom from mitral reoperation at 1, 10, and 20 years
was 99.7%  0.3%, 96.5%  1.4%, and 93.1% 
2.4%, respectively. Several factors were identified on
the Cox analysis to independently predict the risk of
reoperation (Table 4), namely, P2 prolapse (HR, 0.06;
95% CI, 0.008-0.51; P ¼ .037), myxomatous valves (HR,
0.072; 95% CI, 0.008-0.624; P ¼ .017), chordal tendinae
shortening (HR, 9.09; 95% CI, 1.16-18.12; P ¼ .045),
and AF/PHT (HR, 4.20; 95% CI, 1.10-11.20; P ¼ .037).
Impact of Atrial Fibrillation and Pulmonary
Hypertension on Survival and Freedom From
Reoperation
Patients with AF or PHT had their long-term survival
compromised when compared with other asymptomatic
patients without those markers (Figure 2, A). The majority
of these latter patients also had normal LV systolic
dimensions (210 patients with LV end-systolic diameter
<40 mm). After case-matching, long-term survival at 5,
10, and 20 years was 88.8%  3.4%, 75.9%  5.8%,
and 34.1%  24.4%, respectively, for patients with
AF/PHT and 99%  1.0%, 97.5%  1.8%, and
55.7% 16.9%, respectively, for patients without AF/PHT
(P ¼ .013). The benefit of performing operation in patients
without AF/PHT was not present across all ranges of ages.
This advantage seemed prevalent only in younger patients
(65 years) (Figure 2, B, P ¼ .008). In patients aged
more than 65 years, survival was similar in both groups
(Figure 2, C, P ¼ .320).
Patients with AF/PHT were at increased risk for mitral
reoperation over time. Survival free from mitral reoperation
(AF/PHT) at 20 years was 86.3%  6.9% in contrast with
93.7%  3.0% (Figure 3, P ¼ .045).
DISCUSSION
Overall, this was a low-risk population, because patients
were young, were asymptomatic or mildly symptomatic,gery c December 2014
FIGURE 2. A, Overall survival in case-matched population, comparison between patients with and without AF/PHT. B, Overall survival in case-matched
population aged less than 65 years. C, Overall survival in case-matched population aged more than 65 years. AF/PHT, Atrial fibrillation/pulmonary
hypertension.
Coutinho et al Acquired Cardiovascular Diseaseand had few comorbidities. Beyond that, echocardiographic
parameters were suggestive of recent-onset or stable
disease, because signs of LV deterioration, such as
dysfunction and dilatation, were absent. Our policy on
dealing with this subset of patients has been changing
over time toward intervening earlier in the evolution of
the disease, as experience improved, even when the
guidelines gave this group a class II indication, driven by
the high reparability rates achieved and low mortality.
It is now well accepted that MV repair is the procedure of
choice to treat severe degenerativeMR because of its undis-
puted advantages over valve replacement in terms of peri-
operative mortality, preservation of postoperative LVFIGURE 3. Long-term survival free from mitral reoperation, comparison
between patients with and without AF/PHT. AF/PHT, Atrial fibrillation/
pulmonary hypertension.
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Dfunction, and long-term survival.10-13 If an ‘‘early repair
policy’’ is to be considered in asymptomatic patients with
severe MR and preserved LV function, we should aim at
achieving a repair rate of at least 95%, a mortality rate
less than 1%, and a high durability of repair. Several
studies have demonstrated the optimal long-term results
of this strategy.14-17 Nevertheless, most of the studies
have included patients with coronary artery disease,
which is known to decrease survival, and few studies have
evaluated on a long-term basis those patients who are
outside the main surgical indications. Moreover, there is
limited information regarding asymptomatic patients with
preserved LV function with AF or PHT.18,19
There are several logical assumptions that support this
early surgery strategy, and data from our study seem to
reinforce this approach. First, in patients with severe
organic MR, surgery is almost unavoidable, given the
time,20 and the natural history of the disease has shown
that if left untreated, the death rate can reach 10% to
30% per year, once symptoms ensue.21
Second, operating on a patient in NYHA III or IV, or with
LV dysfunction or dilatation (all class I indications) implies
a significant risk, with markedly higher operative and late
postoperative mortality, resulting in an overall 80%
increase in mortality compared with those with no or
minimal symptoms.22,23 Our 30-day mortality was low
(0.8%), probably reflecting a selected population in
whom the negative consequences of chronic MR had not
been established at the time of surgery.
Rosenhek and colleagues6 prospectively followed 132
asymptomatic patients with serial clinical and echo-
cardiographic examinations and referred them to surgery
only when the criteria described in the guidelines were ful-
filled. They concluded that overall survival, including peri-
operative and late deaths, was not statistically different
from expected survival, thus suggesting that asymptomaticdiovascular Surgery c Volume 148, Number 6 2799
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Dpatients could be safely followed up on a regular basis
(6-month intervals) until symptoms occur, or as soon as
they reach the indications recommended by the guidelines.
By contrast, Montant and colleagues16 reported worse
postoperative and late outcomes in these subsets of patients
compared with those who underwent early repair. Even
patients who were closely monitored until surgical triggers
appeared had an impaired late survival compared with
those who had been allocated to an early surgery strategy.
We must bear in mind that initial signs of incipient
decompensation may easily be overlooked and the
appearance of symptoms can be insidious and remain
undetected, particularly in more sedentary patients.
AF and PHT are common complications of chronic MR
and are associated with postoperative, cardiovascular death,
and LV dysfunction.19,24 Current guidelines only consider
them as class IIa indications in this setting, which shows
that there is no clear consensus among experts to
recommend early surgery in these patients.1,2 In the
current work, we have clearly demonstrated that patients
with AF/PHT had worse outcomes than patients who have
not met those criteria, even after successful MV surgery.
AF and PHT were identified as independent predictors of
late mortality in the overall study population, with a
2-fold increased risk. Both factors may present as markers
of chronicity, and it is not known whether patients recover
to normal values of pulmonary artery pressure or regain
sinus rhythm after surgery.
The advantage of operating on patients without AF/PHT
was age-dependent, with the younger subjects (aged<65
years) deriving the most benefit. In older patients, there
was no significant difference between operating earlier
and the development of AF/PHT. Therefore, in this
instance, a conservative approach can be pursued safely
without compromising long-term survival. To the best of
our knowledge, this association has not been demonstrated
by others. Furthermore, patients with AF/PHT were more
prone to undergo a second mitral surgery during their
lifetime compared with those without AF/PHT.
A recent multicenter international study19 evaluated the
outcome implications of PHT in patients with flail leaflets
and found that MV surgery was beneficial but did not
completely abolish the adverse effects of PHT once
established (increased risk of cardiac death and heart
failure). Although the majority of patients in our study
could be included in the same class of indication for surgery
(class IIa) in the latest 2014 American Heart Association/
American College of Cardiology guidelines, patients with
AF/PHT clearly represent a different risk pattern.
Third, reconstructive MV surgery is feasible in the
majority of patients with degenerative MR. The rate of
repair in this particular group of patients has been reported
to be 80% to 100%.5,14-16 We repaired theMVin more than
98% of the cases, including all spectrum of degenerative2800 The Journal of Thoracic and Cardiovascular SurMV pathology, from fibroelastic deficiency to Barlow’s
disease. Most reports do not distinguish mitral pathology,
and we can only speculate that myxomatous disease
probably predominates in studies enrolling younger
patients. This is important, because these valves,
particularly Barlow’s valves, are known to be more
demanding and require highly differentiated expertise.25
We performed MV repair in 65 of these patients, and we
were unable to preserve the native valve in only 1 patient.
Fourth, MV repair has to be a durable procedure if we
want to recommend it early in the clinical evolution of
severeMR. It is better to have a good-functioning prosthesis
than a badly repaired valve, but, in this particular scenario,
replacement of the MV should be viewed as a failure.
Several studies have reported outstanding longevity of the
repair.5,26 In our study, only 12 patients required
reoperation to the MV and only 2 patients had early
failures (we were able to re-repair both). We have
experienced 10 late failures (2.6%) after a mean of
8.7 years. At 22 years of follow-up, 93.1% of patients
were free from mitral reoperation. We leave a word of
caution about the occurrence of artificial chordae rupture,
because it was the cause of failure in 2 patients in this series.
We have previously analyzed this complication and
hypothesized that instrumental manipulation could weaken
the polytetrafluoroethylene.27 Chordal shortening, which
we have used in the early days of MV repair, was found
to be an independent risk factor for reoperation. Flammeng
and colleagues28 also came to this conclusion. The advent
of the use of artificial chordae, with consistent use of
complete annuloplasty rings, allied to the increased use of
intraoperative transesophageal echocardiogram to evaluate
the adequacy of repair has resulted in a higher feasibility
of repair and reduction of need for reoperation. On the
contrary, isolated P2 prolapse was independently associated
with a decreased risk of reoperation, which is similar to
other reports.4,5
Finally, new markers of risk in severe asymptomatic MR
(before class I and IIa indications for surgery) have been
described and could aid in the decision to intervene earlier
or to manage those patients more conservatively. Left atrial
dilatation (volume index 60 mL/m2), neurohormonal
activation (elevated brain natriuretic peptide), functional
capacity, and exercise-induced changes in LV volumes,
ejection fraction, and SPAP all have shown important
correlations with the prognosis of patients.29
Study Limitations
This is a retrospective design and patients were not
randomized, which can always be subject to selection bias
despite the completeness of our follow-up data and the pro-
spective nature of the database from which the data were
retrieved. We do not have complete echocardiographic
information during follow-up (only 65%). However, ingery c December 2014
Coutinho et al Acquired Cardiovascular Diseasethis young population, if relevant MR developed during the
study period, patients would most likely have been sent
back to surgery. Patients were deemed asymptomatic or
mildly symptomatic according to the NYHA functional
classification (class I or II), which has obvious intrinsic
limitations. Patients preferably should have been classified
on the basis of the results of an exercise test.CONCLUSIONS
Our results show that asymptomatic or mildly symptom-
atic patients with severe MR and preserved LV function can
be managed safely with an early surgery strategy, because it
is possible to repair almost all valves, irrespective of the
leaflets involved, with a mortality less than 1% and an
overall survival similar to, if not better than, an age- and
gender-matched population. Asymptomatic patients who
have AF or PHT at the time of surgery are at increased
risk for mortality and mitral reoperation compared with
those who went to surgery early, before those negative
markers appeared. Therefore, careful consideration should
be given with regard to mitral surgery before AF/PHT is
established. Older patients (aged >65 years) can be
managed conservatively until conventional triggers appear
without compromising late survival.A
C
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